Ricardo Gasca-Pineda, Mariana Osorio-Hernández, Roopa Mehta, Jorge Escobedo-de-la-Peña, Carlos A Narváez-Oriani
Objective: To estimate the direct and indirect economic burden of hypercholesterolemia in patients with high risk of a cardiovascular event, specifically there were defined 5 groups of patients: 1) familial hypercholesterolemia; 2, 3 and 4) patients with hypercholesterolemia and background of diabetes, myocardial infarction or stroke; 5) diabetes, myocardial infarction and hypercholesterolemia (very high-risk patients) from the Mexican public healthcare institutions.
Methods: For the estimation of the direct costs the items included correspond to: outpatient care, pharmacological treatment, inpatient hospital care, and surgical procedures. For indirect economic burden, death certificates, before the end of the productive age due to hypercholesterolemia were calculated (premature mortality).
Results: The direct economic burden for the 5 groups of patients at risk is MXN $39,601,464,154 (USD $1,987,526,432), while the indirect economic burden amounts to MXN $121,646,689 (USD $6,105,229).
Conclusions: The economic impact of hypercholesterolemia in patients with high cardiovascular risk is $39,723,110,843 (equivalent to USD $1,993,631,661) and corresponds to the 0.16% of GDP.
{"title":"Economic burden of hypercholesterolemia in high risk of cardiovascular disease population in Mexico.","authors":"Ricardo Gasca-Pineda, Mariana Osorio-Hernández, Roopa Mehta, Jorge Escobedo-de-la-Peña, Carlos A Narváez-Oriani","doi":"10.24875/ACM.22000195","DOIUrl":"https://doi.org/10.24875/ACM.22000195","url":null,"abstract":"<p><strong>Objective: </strong>To estimate the direct and indirect economic burden of hypercholesterolemia in patients with high risk of a cardiovascular event, specifically there were defined 5 groups of patients: 1) familial hypercholesterolemia; 2, 3 and 4) patients with hypercholesterolemia and background of diabetes, myocardial infarction or stroke; 5) diabetes, myocardial infarction and hypercholesterolemia (very high-risk patients) from the Mexican public healthcare institutions.</p><p><strong>Methods: </strong>For the estimation of the direct costs the items included correspond to: outpatient care, pharmacological treatment, inpatient hospital care, and surgical procedures. For indirect economic burden, death certificates, before the end of the productive age due to hypercholesterolemia were calculated (premature mortality).</p><p><strong>Results: </strong>The direct economic burden for the 5 groups of patients at risk is MXN $39,601,464,154 (USD $1,987,526,432), while the indirect economic burden amounts to MXN $121,646,689 (USD $6,105,229).</p><p><strong>Conclusions: </strong>The economic impact of hypercholesterolemia in patients with high cardiovascular risk is $39,723,110,843 (equivalent to USD $1,993,631,661) and corresponds to the 0.16% of GDP.</p>","PeriodicalId":8360,"journal":{"name":"Archivos de cardiologia de Mexico","volume":"93 3","pages":"328-335"},"PeriodicalIF":0.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4a/60/7567AX223-ACM-93-328.PMC10406478.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9956211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Héctor M Jimenez-Vargas, Jorge L Cervantes-Salazar, Liliana López-Hernández, Leonardo Rivera-Rodríguez
*Correspondence: Leonardo Rivera-Rodríguez E-mail: rivleonard@gmail.com Available online: 26-07-2023 Arch Cardiol Mex (Eng). 2023;93(3):362-363 www.archivoscardiologia.com Date of reception: 10-02-2022 Date of acceptance: 16-09-2022 DOI: 10.24875/ACM.22000054 The tricuspid atresia is described as an absence of connection between the right atrium and right ventricle, it’s classified based on the relationship of the great vessels, the existence or absence of pulmonary stenosis, and the characteristics of the ventricular septal defect1. The association with interrupted aortic arch type A is rare. The actual treatment for these patients is palliative, specifically in those with D-transposition of the great vessels and left obstructive outflow tract, the Damus–Kaye–Stansel procedure (DKS) associated
{"title":"Damus-Kaye-Stansel surgery in a patient with tricuspid atresia, transposition of the great arteries, and type A aortic arch interruption.","authors":"Héctor M Jimenez-Vargas, Jorge L Cervantes-Salazar, Liliana López-Hernández, Leonardo Rivera-Rodríguez","doi":"10.24875/ACM.22000054","DOIUrl":"https://doi.org/10.24875/ACM.22000054","url":null,"abstract":"*Correspondence: Leonardo Rivera-Rodríguez E-mail: rivleonard@gmail.com Available online: 26-07-2023 Arch Cardiol Mex (Eng). 2023;93(3):362-363 www.archivoscardiologia.com Date of reception: 10-02-2022 Date of acceptance: 16-09-2022 DOI: 10.24875/ACM.22000054 The tricuspid atresia is described as an absence of connection between the right atrium and right ventricle, it’s classified based on the relationship of the great vessels, the existence or absence of pulmonary stenosis, and the characteristics of the ventricular septal defect1. The association with interrupted aortic arch type A is rare. The actual treatment for these patients is palliative, specifically in those with D-transposition of the great vessels and left obstructive outflow tract, the Damus–Kaye–Stansel procedure (DKS) associated","PeriodicalId":8360,"journal":{"name":"Archivos de cardiologia de Mexico","volume":"93 3","pages":"362-363"},"PeriodicalIF":0.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/07/33/7567AX223-ACM-93-362.PMC10406488.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9956215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
We would like to share ideas on the publication “Acute myocarditis after administration of BNT162b2 vaccine against COVID-191”. Cueva-Recalde et al. present the case of a 28-year-old male patient with no prior medical history who has been experiencing chest pain for the past 3 days1. The patient was hospitalized but remained asymptomatic and did not require treatment1. Cueva-Recalde et al. stated that, while rare, physicians should be aware of this adverse event of COVID-19 vaccination, while bearing in mind its unquestionably positive benefit-risk profile1. We both agree that protecting the COVID-19 is essential and that more study is required to address the major clinical problem. The development of clinical diseases and immunization may be causally related. It might occasionally be difficult to identify the specific path-immunopharmacological link due to ignorance. If a clinical condition is thought to be related to the COVID-19 immunization, there are a few important factors that need to be taken into account. There is a chance of comorbidity. For instance, a concurrent dengue infection and vaccination could result in a clinical illness that was misdiagnosed2. Comorbidity is a likely ailment that might be misdiagnosed as a negative vaccination reaction. It may be difficult to understand how therapy methods are impacted by chronic medical conditions. It could be difficult to understand how persistent medical issues affect therapeutic strategies. The COVID-19, which is currently unidentified, must also be considered3. It is conceivable that a previous COVID-19 pandemic had an impact on the vaccine’s efficiency and results. Infection with COVID-19 may also have an impact on clinical outcomes. It is often challenging to completely rule out the effects of earlier asymptomatic illnesses without the required laboratory investigations. An important auxiliary factor is genetics4. The immune system’s response to certain genetic components may affect how it handles negative vaccine side effects. Understanding how the underlying genetic component impacts the clinical scenario regarding vaccine success would be very beneficial. This problem needs to be resolved if more research is to be done. Summative large-scale data may help researchers better comprehend the COVID19 vaccine’s effects.
{"title":"Acute myocarditis after administration of COVID-19 vaccine: comment.","authors":"Amnuay Kleebayoon, Viroj Wiwanitkit","doi":"10.24875/ACM.23000079","DOIUrl":"https://doi.org/10.24875/ACM.23000079","url":null,"abstract":"We would like to share ideas on the publication “Acute myocarditis after administration of BNT162b2 vaccine against COVID-191”. Cueva-Recalde et al. present the case of a 28-year-old male patient with no prior medical history who has been experiencing chest pain for the past 3 days1. The patient was hospitalized but remained asymptomatic and did not require treatment1. Cueva-Recalde et al. stated that, while rare, physicians should be aware of this adverse event of COVID-19 vaccination, while bearing in mind its unquestionably positive benefit-risk profile1. We both agree that protecting the COVID-19 is essential and that more study is required to address the major clinical problem. The development of clinical diseases and immunization may be causally related. It might occasionally be difficult to identify the specific path-immunopharmacological link due to ignorance. If a clinical condition is thought to be related to the COVID-19 immunization, there are a few important factors that need to be taken into account. There is a chance of comorbidity. For instance, a concurrent dengue infection and vaccination could result in a clinical illness that was misdiagnosed2. Comorbidity is a likely ailment that might be misdiagnosed as a negative vaccination reaction. It may be difficult to understand how therapy methods are impacted by chronic medical conditions. It could be difficult to understand how persistent medical issues affect therapeutic strategies. The COVID-19, which is currently unidentified, must also be considered3. It is conceivable that a previous COVID-19 pandemic had an impact on the vaccine’s efficiency and results. Infection with COVID-19 may also have an impact on clinical outcomes. It is often challenging to completely rule out the effects of earlier asymptomatic illnesses without the required laboratory investigations. An important auxiliary factor is genetics4. The immune system’s response to certain genetic components may affect how it handles negative vaccine side effects. Understanding how the underlying genetic component impacts the clinical scenario regarding vaccine success would be very beneficial. This problem needs to be resolved if more research is to be done. Summative large-scale data may help researchers better comprehend the COVID19 vaccine’s effects.","PeriodicalId":8360,"journal":{"name":"Archivos de cardiologia de Mexico","volume":"93 3","pages":"382-383"},"PeriodicalIF":0.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/54/7f/7567AX223-ACM-93-382.PMC10406480.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9993760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
José E Duarte-Arguello, Mario R García-Arias, José A Alvarado-Alvarado
{"title":"Anomaly of the origin of the coronary arteries, can it lead to cardiogenic shock?","authors":"José E Duarte-Arguello, Mario R García-Arias, José A Alvarado-Alvarado","doi":"10.24875/ACM.22000189","DOIUrl":"https://doi.org/10.24875/ACM.22000189","url":null,"abstract":"","PeriodicalId":8360,"journal":{"name":"Archivos de cardiologia de Mexico","volume":"93 3","pages":"376-379"},"PeriodicalIF":0.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4c/6d/7567AX223-ACM-93-376.PMC10406469.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9997417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alejandra Ruiz-Aranjuelo, Maruan C Chabbar-Boudet, Elena P Gambó-Ruberte, Carmen Albarrán-Martín, Carmen Untoria-Agustín, Fernando Garza-Benito
Objectives: Cardiac Rehabilitation Programs (CRP) are an excellent tool to achieve adherence to therapeutic. The aim of our study was analyzing at the medium-term adherence, as well as identifying low adherence predictors to pharmacological therapeutic compliance and changes in lifestyle.
Methods: Retrospective study of 100 patients referred to a CRP in 2018 after presenting ACS. At the one-year review adherence to diet, physical exercise, and smoking cessation were analyzed. Optimal adherence was considered if all three items were met. Compliance with taking medication was also studied using the Morisky-Green test. Finally, low adherence predictors were analyzed by lineal/logistic regression analysis.
Results: 98% of the patients presented acceptable adherence to the Mediterranean diet, 83% good adherence to physical exercise, and 79% of the smokers achieved the cessation of smoking. Regarding drug adherence, 97% of the patients complied correctly. 68% of the patients achieved good overall adherence. Eastern European nationality, sedentary lifestyle, and home-based CRP were predictors of low adherence. The youngest patients and the "blue collar" occupation showed a tendency to poor adherence, although not significantly.
Conclusions: In our environment there is good medium-term adherence to lifestyle changes and pharmacological compliance in patients who complete CRP after ACS. Eastern European nationality, sedentary lifestyle, and home-based programs were associated with poor adherence.
{"title":"Analysis of medium-term adherence after the implementation of a cardiac rehabilitation program.","authors":"Alejandra Ruiz-Aranjuelo, Maruan C Chabbar-Boudet, Elena P Gambó-Ruberte, Carmen Albarrán-Martín, Carmen Untoria-Agustín, Fernando Garza-Benito","doi":"10.24875/ACM.21000156","DOIUrl":"https://doi.org/10.24875/ACM.21000156","url":null,"abstract":"<p><strong>Objectives: </strong>Cardiac Rehabilitation Programs (CRP) are an excellent tool to achieve adherence to therapeutic. The aim of our study was analyzing at the medium-term adherence, as well as identifying low adherence predictors to pharmacological therapeutic compliance and changes in lifestyle.</p><p><strong>Methods: </strong>Retrospective study of 100 patients referred to a CRP in 2018 after presenting ACS. At the one-year review adherence to diet, physical exercise, and smoking cessation were analyzed. Optimal adherence was considered if all three items were met. Compliance with taking medication was also studied using the Morisky-Green test. Finally, low adherence predictors were analyzed by lineal/logistic regression analysis.</p><p><strong>Results: </strong>98% of the patients presented acceptable adherence to the Mediterranean diet, 83% good adherence to physical exercise, and 79% of the smokers achieved the cessation of smoking. Regarding drug adherence, 97% of the patients complied correctly. 68% of the patients achieved good overall adherence. Eastern European nationality, sedentary lifestyle, and home-based CRP were predictors of low adherence. The youngest patients and the \"blue collar\" occupation showed a tendency to poor adherence, although not significantly.</p><p><strong>Conclusions: </strong>In our environment there is good medium-term adherence to lifestyle changes and pharmacological compliance in patients who complete CRP after ACS. Eastern European nationality, sedentary lifestyle, and home-based programs were associated with poor adherence.</p>","PeriodicalId":8360,"journal":{"name":"Archivos de cardiologia de Mexico","volume":"93 2","pages":"131-138"},"PeriodicalIF":0.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d0/72/7567AX222-ACM-93-131.PMC10161818.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10259220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yván R Persia-Paulino, Javier Cuevas-Pérez, Rodrigo Fernández-Asensio, Alejandro Junco-Vicente, Lisardo Iglesias-Fraile, Ana Ayesta
Coronary artery vasospasm is a cause of chest pain described more than 50 years ago by Prinzmetal et al., named as variant angina1. Now, it is commonly known as Prinzmetal angina or vasospastic angina (VA). Patients with VA have episodes of oppressive chest pain, characterized by diurnal variation and not with exercise (even at rest), that have good response to short acting oral nitrates and oral calcium channel blockers (CCB)1. Some patients with VA develop malignant ventricular arrythmias during ischemic episodes that lead to sudden death2. Although VA usually has a good response to oral nitrates and oral CCB, treatment of patients that cannot tolerate oral drugs (on the acute phase of sudden death, hemodynamically unstable or patients on mechanical ventilation) options are very reduced. In this case report, we present a patient with an outpatient aborted sudden death due to VA with frequent episodes of coronary arteries vasospasms with malignant ventricular arrythmias refractory to intravenous nitrates that responded to clevidipine, an intravenous CCB. A 65-years-old male patient was brought to the emergency room due to out-of-hospital cardiac arrest. Past medical history of hypertriglyceridemia and was an active smoker. Chronic medication included atorvastatin 20 mg once daily (OD) and acetylsalicylic acid 100 mg (OD). The patient suffered cardiac arrest while traveling on public bus and basic life support maneuvers were started until medical assistance arrived. The automated external defibrillator showed a ventricular fibrillation (VF) and after 2 shocks of 200 Joules (J) and 15 min of cardiopulmonary resuscitation maneuvers the patient recovered pulse. The 12-lead electrocardiogram (ECG) showed sinus tachycardia without signs of myocardial ischemia. The patient was transferred to the hospital with mechanical ventilation support. Once on the emergency room, the patient was hemodynamically stable without vasoactive drugs. No remarkable findings on physical examination. The ECG showed a sinus tachycardia without alterations suggestive of myocardial ischemia (Fig. 1A). An emergency echocardiogram was performed and normal size non-hypertrophic left ventricle with mild global hypokinesia (no regional alterations in contraction suggestive of coronary artery disease) was found. Anyways, hemodynamics laboratory was contacted for an urgent coronarography to exclude myocardial ischemia as the cause of VF.
{"title":"Malignant coronary vasospasm refractory to nitrates: Using clevidipine as an emergent coronary vasodilator.","authors":"Yván R Persia-Paulino, Javier Cuevas-Pérez, Rodrigo Fernández-Asensio, Alejandro Junco-Vicente, Lisardo Iglesias-Fraile, Ana Ayesta","doi":"10.24875/ACM.21000251","DOIUrl":"https://doi.org/10.24875/ACM.21000251","url":null,"abstract":"Coronary artery vasospasm is a cause of chest pain described more than 50 years ago by Prinzmetal et al., named as variant angina1. Now, it is commonly known as Prinzmetal angina or vasospastic angina (VA). Patients with VA have episodes of oppressive chest pain, characterized by diurnal variation and not with exercise (even at rest), that have good response to short acting oral nitrates and oral calcium channel blockers (CCB)1. Some patients with VA develop malignant ventricular arrythmias during ischemic episodes that lead to sudden death2. Although VA usually has a good response to oral nitrates and oral CCB, treatment of patients that cannot tolerate oral drugs (on the acute phase of sudden death, hemodynamically unstable or patients on mechanical ventilation) options are very reduced. In this case report, we present a patient with an outpatient aborted sudden death due to VA with frequent episodes of coronary arteries vasospasms with malignant ventricular arrythmias refractory to intravenous nitrates that responded to clevidipine, an intravenous CCB. A 65-years-old male patient was brought to the emergency room due to out-of-hospital cardiac arrest. Past medical history of hypertriglyceridemia and was an active smoker. Chronic medication included atorvastatin 20 mg once daily (OD) and acetylsalicylic acid 100 mg (OD). The patient suffered cardiac arrest while traveling on public bus and basic life support maneuvers were started until medical assistance arrived. The automated external defibrillator showed a ventricular fibrillation (VF) and after 2 shocks of 200 Joules (J) and 15 min of cardiopulmonary resuscitation maneuvers the patient recovered pulse. The 12-lead electrocardiogram (ECG) showed sinus tachycardia without signs of myocardial ischemia. The patient was transferred to the hospital with mechanical ventilation support. Once on the emergency room, the patient was hemodynamically stable without vasoactive drugs. No remarkable findings on physical examination. The ECG showed a sinus tachycardia without alterations suggestive of myocardial ischemia (Fig. 1A). An emergency echocardiogram was performed and normal size non-hypertrophic left ventricle with mild global hypokinesia (no regional alterations in contraction suggestive of coronary artery disease) was found. Anyways, hemodynamics laboratory was contacted for an urgent coronarography to exclude myocardial ischemia as the cause of VF.","PeriodicalId":8360,"journal":{"name":"Archivos de cardiologia de Mexico","volume":"92 4","pages":"537-540"},"PeriodicalIF":0.5,"publicationDate":"2022-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/97/aa/6936AX214-ACM-92-537.PMC9681519.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10325130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Battioni Luciano, Cristhian E Scatularo, Sebastián Bellia, Adrián Lescano, Stella M Pereiro, Julio Giorgini
{"title":"[Determinantes del puntaje PHQ 9 para síntomas depresivos mayores en trabajadores de la salud durante la pandemia de COVID-19 mediante técnicas de <i>machine learning</i>].","authors":"Battioni Luciano, Cristhian E Scatularo, Sebastián Bellia, Adrián Lescano, Stella M Pereiro, Julio Giorgini","doi":"10.24875/ACM.22000101","DOIUrl":"10.24875/ACM.22000101","url":null,"abstract":"","PeriodicalId":8360,"journal":{"name":"Archivos de cardiologia de Mexico","volume":" ","pages":"87-93"},"PeriodicalIF":0.5,"publicationDate":"2022-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33529269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Kietseé A Díaz-Domínguez, Andrés Cruz-Melendez, Luis M Amezcua-Castillo, Jazmin A Guerra-López, Claudia Tavera-Alonso, Héctor González-Pacheco, Luis M Amezcua-Guerra
Objective: The aim of the study was to assess whether a recent SARS-CoV-2 infection could by itself be a risk or prognostic factor for ST-segment elevation myocardial infarction (STEMI).
Method: An observational study in unvaccinated patients with STEMI confirmed by cardiac catheterization was conducted. A recent or concurrent SARS-CoV-2 infection was identified by the presence of serum IgG against the nucleocapsid protein, or a positive polymerase chain reaction test on nasopharyngeal swabs. Baseline cardiovascular risk factors, clinical STEMI severity, main catheterization findings, and occurrence of major adverse cardiovascular events (MACE) during hospitalization were compared between study subgroups.
Results: Of a total of 89 patients recruited, 14 (16%) had a recent SARS-CoV-2 infection. Patients with STEMI and recent SARS-CoV-2 infection had a markedly lower frequency of high blood pressure (20% versus 55%; P = 0.03) as well as a tendency to have fewer comorbidities. Regarding the clinical presentation, there were no differences in the severity of the STEMI. Furthermore, the main findings during cardiac catheterization including the atherosclerotic burden and the number of vessels affected, as well as the occurrence of MACE during follow-up, were not significantly different between the groups.
Conclusions: A recent SARS-CoV-2 infection appears to facilitate the triggering of STEMI, as these patients have fewer traditional cardiovascular risk factors than their uninfected counterparts. However, this does not seem to affect the clinical presentation or the in-hospital course of STEMI patients.
{"title":"Should a recent SARS-CoV-2 infection be considered a risk or prognostic factor for ST-segment elevation myocardial infarction?","authors":"Kietseé A Díaz-Domínguez, Andrés Cruz-Melendez, Luis M Amezcua-Castillo, Jazmin A Guerra-López, Claudia Tavera-Alonso, Héctor González-Pacheco, Luis M Amezcua-Guerra","doi":"10.24875/ACM.22000153","DOIUrl":"10.24875/ACM.22000153","url":null,"abstract":"<p><strong>Objective: </strong>The aim of the study was to assess whether a recent SARS-CoV-2 infection could by itself be a risk or prognostic factor for ST-segment elevation myocardial infarction (STEMI).</p><p><strong>Method: </strong>An observational study in unvaccinated patients with STEMI confirmed by cardiac catheterization was conducted. A recent or concurrent SARS-CoV-2 infection was identified by the presence of serum IgG against the nucleocapsid protein, or a positive polymerase chain reaction test on nasopharyngeal swabs. Baseline cardiovascular risk factors, clinical STEMI severity, main catheterization findings, and occurrence of major adverse cardiovascular events (MACE) during hospitalization were compared between study subgroups.</p><p><strong>Results: </strong>Of a total of 89 patients recruited, 14 (16%) had a recent SARS-CoV-2 infection. Patients with STEMI and recent SARS-CoV-2 infection had a markedly lower frequency of high blood pressure (20% versus 55%; P = 0.03) as well as a tendency to have fewer comorbidities. Regarding the clinical presentation, there were no differences in the severity of the STEMI. Furthermore, the main findings during cardiac catheterization including the atherosclerotic burden and the number of vessels affected, as well as the occurrence of MACE during follow-up, were not significantly different between the groups.</p><p><strong>Conclusions: </strong>A recent SARS-CoV-2 infection appears to facilitate the triggering of STEMI, as these patients have fewer traditional cardiovascular risk factors than their uninfected counterparts. However, this does not seem to affect the clinical presentation or the in-hospital course of STEMI patients.</p>","PeriodicalId":8360,"journal":{"name":"Archivos de cardiologia de Mexico","volume":" ","pages":"16-21"},"PeriodicalIF":0.5,"publicationDate":"2022-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33449741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Juan G Chiabrando, Fernando D Garagoli, Maria M Abraham Foscolo, Giuliana Corna, Maria de Los Milagros Fleitas, Juan Valle-Raleigh, Horacio A Medina de Chazal, Daniel H Berrocal, Jose M Rabellino, Ignacio M Bluro
Background: Peripheral artery disease (PAD) frequently affects multiple segments of the limbs. Contradictory data have reported worse prognosis in aortoiliac lesions, nevertheless, diabetes and chronic limb ischemia frequently affects the infrapatellar territory. Our aim was to assess the impact of infrapatellar disease in cardiovascular outcomes.
Methods: We performed a retrospective, observational cohort study at a university hospital in Argentina. Electronic health records were retrospectively reviewed including symptomatic PAD patients requiring revascularization. A multivariable regression model was performed to account for confounders. The primary endpoint was a composite of hospitalizations due to chronic limb threatening ischemia (CLTI) and major amputation events between infrapatellar and suprapatellar patients. Minor amputation events, all-cause death, myocardial infarction (MI), stroke, and major cardiovascular events (MACE) were secondary endpoints.
Results: From January 2014 through July 2020, a total of 309 patients were included in the analysis. 151 patients had suprapatellar disease, and 158 had infrapatellar disease. The primary composite endpoint occurred in 35 patients (22.2%) in the infrapatellar patients and 18 patients (11.9%) in the suprapatellar patients (HR = 2.16; 95% confidence interval [CI]= [1.22-3.82]; p = 0.008). Both components of the primary outcomes occurred more frequently in infrapatellar patients.Minor amputation events were more prevalent in infrapatellar patients (HR = 5.09; 95% CI = [1.47-17.6]; p = 0.010). Death,MI, stroke, and MACE events were not different among groups (all p > 0.05).
Conclusion: Infrapatellar disease was anindependent factor for increased hospitalization of CLTI, major and minor amputations events, compared to suprapatellardisease in symptomatic revascularized PAD patients.
{"title":"Clinical impact of the infrapatellar location in symptomatic peripheral arterial disease patients.","authors":"Juan G Chiabrando, Fernando D Garagoli, Maria M Abraham Foscolo, Giuliana Corna, Maria de Los Milagros Fleitas, Juan Valle-Raleigh, Horacio A Medina de Chazal, Daniel H Berrocal, Jose M Rabellino, Ignacio M Bluro","doi":"10.24875/ACM.22000161","DOIUrl":"https://doi.org/10.24875/ACM.22000161","url":null,"abstract":"<p><strong>Background: </strong>Peripheral artery disease (PAD) frequently affects multiple segments of the limbs. Contradictory data have reported worse prognosis in aortoiliac lesions, nevertheless, diabetes and chronic limb ischemia frequently affects the infrapatellar territory. Our aim was to assess the impact of infrapatellar disease in cardiovascular outcomes.</p><p><strong>Methods: </strong>We performed a retrospective, observational cohort study at a university hospital in Argentina. Electronic health records were retrospectively reviewed including symptomatic PAD patients requiring revascularization. A multivariable regression model was performed to account for confounders. The primary endpoint was a composite of hospitalizations due to chronic limb threatening ischemia (CLTI) and major amputation events between infrapatellar and suprapatellar patients. Minor amputation events, all-cause death, myocardial infarction (MI), stroke, and major cardiovascular events (MACE) were secondary endpoints.</p><p><strong>Results: </strong>From January 2014 through July 2020, a total of 309 patients were included in the analysis. 151 patients had suprapatellar disease, and 158 had infrapatellar disease. The primary composite endpoint occurred in 35 patients (22.2%) in the infrapatellar patients and 18 patients (11.9%) in the suprapatellar patients (HR = 2.16; 95% confidence interval [CI]= [1.22-3.82]; p = 0.008). Both components of the primary outcomes occurred more frequently in infrapatellar patients.Minor amputation events were more prevalent in infrapatellar patients (HR = 5.09; 95% CI = [1.47-17.6]; p = 0.010). Death,MI, stroke, and MACE events were not different among groups (all p > 0.05).</p><p><strong>Conclusion: </strong>Infrapatellar disease was anindependent factor for increased hospitalization of CLTI, major and minor amputations events, compared to suprapatellardisease in symptomatic revascularized PAD patients.</p>","PeriodicalId":8360,"journal":{"name":"Archivos de cardiologia de Mexico","volume":"93 3","pages":"318-327"},"PeriodicalIF":0.5,"publicationDate":"2022-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/23/01/7567AX223-ACM-93-318.PMC10406486.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9984810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mario R García-Arias, Jorge E -Tovilla, Jorge I García-Espinoza, Uriel Encarnación-Martínez, Rodrigo Gopar-Nieto, José L Briseño-De la Cruz
Mario R. García-Arias1,2*, Jorge E. Reyes-Tovilla1,2, Jorge I. García-Espinoza1,2, Uriel Encarnación-Martínez1,2, Rodrigo Gopar-Nieto3, and José L. Briseño-De la Cruz3 1Department of Cardiology, Instituto Nacional de Cardiología “Ignacio Chávez”; 2School of Medicine, Universidad Nacional Autónoma de México; 3Coronary Care Unit, Instituto Nacional de Cardiología “Ignacio Chávez”. Mexico City, Mexico SCIENTIFIC LETTER
{"title":"Cardiogenic shock as the initial manifestation of takotsubo syndrome.","authors":"Mario R García-Arias, Jorge E -Tovilla, Jorge I García-Espinoza, Uriel Encarnación-Martínez, Rodrigo Gopar-Nieto, José L Briseño-De la Cruz","doi":"10.24875/ACM.20000464","DOIUrl":"https://doi.org/10.24875/ACM.20000464","url":null,"abstract":"Mario R. García-Arias1,2*, Jorge E. Reyes-Tovilla1,2, Jorge I. García-Espinoza1,2, Uriel Encarnación-Martínez1,2, Rodrigo Gopar-Nieto3, and José L. Briseño-De la Cruz3 1Department of Cardiology, Instituto Nacional de Cardiología “Ignacio Chávez”; 2School of Medicine, Universidad Nacional Autónoma de México; 3Coronary Care Unit, Instituto Nacional de Cardiología “Ignacio Chávez”. Mexico City, Mexico SCIENTIFIC LETTER","PeriodicalId":8360,"journal":{"name":"Archivos de cardiologia de Mexico","volume":"92 3","pages":"412-414"},"PeriodicalIF":0.5,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/44/94/6936AX213-ACM-92-412.PMC9262287.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39520288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}